Improving Learning and Memory in Portuguese Patients With Multiple Sclerosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorCentro Hospitalar De São João, E.P.E.

About this trial

Deficits in memory and learning are common in Multiple Sclerosis, posing significant challenges in patients' daily lives. Cognitive rehabilitation has been shown to be effective in ameliorating these deficits, with programs such as the Modified Story Memory Technique (mSMT). In Portugal, no studies tested the efficacy of memory training programs. We aim to fill that gap by translating and developing mSMT, conducting a randomized double-blind, placebo-control, clinical trial, and, therefore, testing its efficacy through objective measures of cognitive function, and the maintenance of its benefits longitudinally. Patients with documented impairment in new learning abilities will be recruited at Centro Hospitalar Universitario São João, and randomly assigned to a memory retraining group or an active control group. Both groups will undergo baseline, immediate, and long-term follow-up assessments consisting of (1) a neuropsychological comprehensive assessment and (2) self-reported questionnaires regarding symptoms of anxiety, depression, fatigue, quality of life, and sleep. Optional enrollment in pre-post neuroimaging will also allow us to look at changes in the brain.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

established diagnosis of MS, according to McDonald criteria;

adult native Portuguese speakers;

at least four years of education;

free of exacerbations and use of steroids for at least one month, and no neurologic history other than MS;

Disqualifiers

an exacerbation within one month;

neurological history of head injury, stroke, seizures, or any other significant neurological history;

patients on steroids, benzodiazepines, and/or neuroleptics;

patients with an active diagnosis of Major Depressive Disorder, Schizophrenia, Bipolar Disorder;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Learning and Memory Training

    Behavioral

    The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context. Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions).

  • Placebo Comparator

    Behavioral

    The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Intervention GroupExperimental treatment 1 intervention
Group B: Placebo Control GroupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Verbal memory

Selective Reminding Test from Brief Repeatable Battery of Neuropsychological Tests (BRBN-T), with higher scores mean better outcome performance.

Time frame
Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.
2

Verbal memory

California Verbal Learning Test II from Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), with higher scores mean better outcome performance.

Time frame
Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.

Secondary outcomes

1

Self-reported Questionnaires

Hospital Anxiety and Depression Scale (HADS), a self-assessed questionnaire consisting of 14 items (0-3 Likert scale) assessing symptoms of depression (HADS-D subscale) and anxiety (HADS-A subscale).

Time frame
Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.
2

Self-reported Questionnaires

Modified Fatigue Impact Scale (MFIS), with a score range of 0-84 for each item, with the highest score indicating greater fatigue severity.

Time frame
Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centro Hospitalar De São João, E.P.E.

Lead sponsor

Instituto de Saude Publica da Universidade do Porto

Collaborator

Universidade do Porto

Collaborator